Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: This mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs

Journal of Cellular Physiology

Volumn 230, Issue 1, 2015, Pages 43-51

  Fons, Pierre ^a   Gueguen Dorbes, Geneviève ^a   Herault, Jean Pascal ^a   Geronimi, Fabien ^a   Tuyaret, Joël ^a   Frédérique, Dol ^a   Schaeffer, Paul ^a   Volle Challier, Cécile ^a   Herbert, Jean Marc ^a   Bono, Françoise ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR ANTAGONIST; SODIUM 2 AMINO 5[(1 METHOXY 2 METHYLINDOLIZIN 3 YL)CARBONYL]BENZOATE; UNCLASSIFIED DRUG; ANTHRANILIC ACID DERIVATIVE; CD133 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GLYCOPROTEIN; INDOLIZINE DERIVATIVE; LEUKOCYTE ANTIGEN; MESSENGER RNA; PEPTIDE; SSR128129E;

ALLOSTERISM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL ADHESION; CELL LINE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; BONE MARROW CELLS; CARCINOMA, LEWIS LUNG; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; INDOLIZINES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; ORTHO-AMINOBENZOATES; PEPTIDES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84906845475     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24656     Document Type: Article

References (45)

1. Ahn GO, Brown JM. 2009. Role of endothelial progenitors ad other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 12:159-164.
2. Anzai H, Nagayoshi M, Obata M, Ikawa Y, Atsumi T. 1999. Self-renewal and differentiation of a basic fibroblast growth factor-dependent multipotent hematopoietic cell line derived from embryonic stem cells. Dev Growth Differ 41:51-58.
3. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. 1999a. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228.
4. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. 1999b. VEGF contributes to postnatal neovascularization by mobilizing bone marrowderived endothelial progenitor cells. EMBO J 18:3964-3972.
5. Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL, Teicher BA. 2003. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 63:5866-5873.
6. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M, Jonckx B, Murakami M, Lanahan AA, Michielsen C, Sibrac D, Dol-Gleizes F, Mazzone M, Zacchigna S, Herault JP, Fischer C, Rigon P, Ruiz de Almodovar C, Claes F, Blanc I, Poesen K, Zhang J, Segura I, Gueguen G, Bordes MF, Lambrechts D, Broussy R, van de Wouwer M, Michaux C, Shimada T, Jean I, Blacher S, Noel A, Motte P, Rom E, Rakic JM, Katsuma S, Schaeffer P, Yayon A, Van Schepdael A, Schwalbe H, Gervasio FL, Carmeliet G, Rozensky J, Dewerchin M, Simons M, Christopoulos A, Herbert JM, Carmeliet P. 2013. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 23:477-488.
7. Burger PE, Coetzee S, McKeehan WL, Kan M, Cook P, Fan Y, Suda T, Hebbel RP, Novitzky N, Muller WA, Wilson EL. 2002. Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood 100:3527-3535.
8. Cai WB, Zhang Y, Cheng R, Wang Z, Fang SH, Xu ZM, YaX, Yang ZH, Ma JX, Shao CK, Gao GQ. 2012. Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway. PLoS ONE 7.
9. Cao Y, Cao R, Hedlund EM. 2008. Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med 86:785-789.
10. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L, Bertolini F. 2003. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9:377-382.
11. Cox CM, Poole TJ. 2000. Angioblast differentiation is influenced by the local environment: FGF-2 induces angioblasts and patterns vessel formation in the quail embryo. Dev Dyn 218:371-382.
12. Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF, Nienhuis AW. 2001. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.Clin Cancer Res 7:2870-2879.
13. Folkman J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
14. Fons P, Herault JP, Delesque N, Tuyaret J, Bono F, Herbert JM. 2004. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 200:351-359.
15. Gabbianelli M, Sargiacomo M, Pelosi E, Testa U, Isacchi G, Peschle C. 1990. "Pure" human hematopoietic progenitors: Permissive action of basic fibroblast growth factor. Science 249:1561-1564.
16. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K,OtteM, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B,HossfeldDK, FiedlerW. 2000. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:3106-3112.
17. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW. 2002. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 8:607-612.
18. Higuchi R, Fockler C, Dollinger G, Watson R. 1993. Kinetic PCR analysis: Real-time monitoring of DNA amplification reactions. Biotechnology (NY) 11:1026-1030.
19. Janowska-Wieczorek A, Majka M, Ratajczak J, Ratajczak MZ. 2001. Autocrine/paracrine mechanisms in human hematopoiesis. Stem Cells 19:99-107.
20. Jung MH, Lee SH, Ahn EM, Lee YM. 2009. Decursin and decursinol angelate inhibit VEGFinduced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 30:655-661.
21. Jung SY, Choi JH, Kwon SM, Masuda H, Asahara T, Lee YM. 2012. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. J Cell Biochem 113:1478-1487.
22. Kalka C, Tehrani H, Laudenberg B, Vale PR, Isner JM, Asahara T, Symes JF. 2000. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 70:829-834.
23. Klint P, Claesson-Welsh L. 1999. Signal transduction by fibroblast growth factor receptors. Front Biosci 4:D165-D177.
24. Korc M, Friesel RE. 2009. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 9:639-651.
25. Li X, Tjwa M, Moons L, Fons P, Noel A, Ny A, Zhou JM, Lennartsson J, Li H, Luttun A, Ponten A, Devy L, Bouche A, Oh H, Manderveld A, Blacher S, Communi D, Savi P, Bono F, Dewerchin M, Foidart JM, Autiero M, Herbert JM, Collen D, Heldin CH, Eriksson U, Carmeliet P. 2005. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 115:118-127.
26. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L,WuY, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. 2001. Impaired recruitment of bone-marrow-derived endothelial mand hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201.
27. Magnusson PU, Ronca R, Dell'era P, Carlstedt P, Jakobsson L, Partanen J, Dimberg A, Claesson-Welsh L. 2005. Fibroblast growth factor receptor-1 expression is required for hematopoietic but not endothelial cell development. Arterioscler Thromb Vasc Biol 25:944-949.
28. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L. 2005. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105:199-206.
29. Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, ScheinbergDA,Benezra R,MittalV.2007.Bonemarrow-derivedendothelial progenitorcells are a major determinant of nascent tumor neovascularization. Genes Dev 21:1546-1558.
30. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. 2002. Bone marrowderived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 8:1004-1010.
31. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. 2000. Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 95:952-958.
32. Poole TJ, Finkelstein EB, Cox CM. 2001. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn 220:1-17.
33. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. 2005. Fibroblast growth factor/ fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev16:159-178.
34. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. 2001. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 115:186-194.
35. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. 2002. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 109:337-346.
36. Ribatti D. 2004. The involvement of endothelial progenitor cells in tumor. J Cell Mol Med 8:294-300.
37. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. 2000. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 106:571-578.
38. Schneider M, Tjwa M, Carmeliet P. 2005. A surrogate marker to monitor angiogenesis at last. Cancer Cell 7:3-4.
39. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP, Jr, Folkman J, Soker S. 2003. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63:8345-8350.
40. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ,D'Amato RJ, Kerbel RS. 2005. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101-111.
41. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. 2002. Smooth muscle progenitor cells in human blood. Circulation 106:1199-1204.
42. Tepper OM, Capla JM, Galiano RD, Ceradini DJ, Callaghan MJ, Kleinman ME, Gurtner GC. 2005. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 105:1068-1077.
43. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW,Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147.
44. Wilson EL, Rifkin DB, Kelly F, Hannocks MJ, Gabrilove JL. 1991. Basic fibroblast growth factor stimulates myelopoiesis in long-term human bone marrow cultures. Blood 77:954-960.
45. Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, Ghermazien H, Brekhman V, Suss-Toby E, Adam D, Shaked Y, Smith V, Neufeld G. 2013. Lysyl oxidaselike-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis.